MedPath

Galderma Group AG

🇨🇭Switzerland
Ownership
-
Employees
-
Market Cap
$22.9B
Website
http://www.galderma.com/

Efficacy and Safety Study of CD2027 Ointment 3 Microgram Per Gram (mcg/g) Twice Daily Treatment for Adults With at Least Moderate Atopic Dermatitis

Phase 2
Completed
Conditions
Atopic Dermatitis
Interventions
Drug: CD2027 Ointment 3 mcg/g, twice daily
Drug: Vehicle Ointment, twice daily
First Posted Date
2009-06-12
Last Posted Date
2022-07-19
Lead Sponsor
Galderma R&D
Target Recruit Count
102
Registration Number
NCT00919763
Locations
🇺🇸

Helendale Dermatology & Medical Spa, LLC, Rochester, New York, United States

🇺🇸

Minnesota Clinical Study Center, Fridley, Minnesota, United States

🇺🇸

Therapeutics Clinical Research, Inc., San Diego, California, United States

and more 11 locations

Evaluate Effectiveness of Epiduo® Gel in Reducing Antibiotic Sensitive & Resistant Strains of Propionibacterium (P)Acnes

Phase 4
Completed
Conditions
P Acnes Colonization
Interventions
First Posted Date
2009-05-22
Last Posted Date
2022-08-01
Lead Sponsor
Galderma R&D
Target Recruit Count
30
Registration Number
NCT00907101
Locations
🇺🇸

Skin Study Center, Broomall, Pennsylvania, United States

ORCA - Oracea® for Rosacea: A Community-based Assessment

First Posted Date
2009-05-04
Last Posted Date
2022-08-25
Lead Sponsor
Galderma R&D
Target Recruit Count
1421
Registration Number
NCT00892281
Locations
🇺🇸

REGISTRAT® - MAP1, Inc. (CRO), Lexington, Kentucky, United States

Comparison of Four Different Regimens of Adapalene 0.1% / Benzoyl Peroxide 2.5% Gel in Acne Vulgaris

Phase 3
Completed
Conditions
Acne
Interventions
Drug: Adapalene-BPO Gel standard+Cetaphil® Moisturizing Lotion
Drug: Adapalene-BPO 3-hour daily application before bedtime
Drug: Adapalene-BPO Gel every other day application
First Posted Date
2009-04-17
Last Posted Date
2021-02-18
Lead Sponsor
Galderma R&D
Target Recruit Count
123
Registration Number
NCT00883233
Locations
🇨🇦

Galderma Investigational Site, Montreal, Quebec, Canada

Clobetasol Propionate Spray Versus Vehicle Spray for the Management of Moderate to Severe Plaque Psoriasis of the Scalp

Phase 4
Completed
Conditions
Scalp Psoriasis
Interventions
First Posted Date
2009-04-15
Last Posted Date
2022-08-25
Lead Sponsor
Galderma R&D
Target Recruit Count
81
Registration Number
NCT00881868
Locations
🇺🇸

Hudson Dermatology, Evansville, Indiana, United States

🇺🇸

Dermatology Associates, PLLC, Seattle, Washington, United States

🇺🇸

Research Division of The Skin Specialty Group, New York, New York, United States

and more 1 locations

Clobetasol Propionate 0.05% Shampoo in Association With Antifungal Shampoo in Scalp Seborrheic Dermatitis

First Posted Date
2009-03-17
Last Posted Date
2021-02-18
Lead Sponsor
Galderma R&D
Target Recruit Count
326
Registration Number
NCT00862654
Locations
🇲🇽

Galderma Investigational Center, Zapopan, Jalisco, Mexico

Pharmacokinetic (PK) and Pharmacodynamic (PD) Study of CD 2027 Spray in Adults With Plaque-type Psoriasis

Phase 2
Completed
Conditions
Plaque-type Psoriasis
Interventions
First Posted Date
2008-10-01
Last Posted Date
2021-02-18
Lead Sponsor
Galderma R&D
Target Recruit Count
26
Registration Number
NCT00763503
Locations
🇺🇸

J & S Studies, Bryan, Texas, United States

🇺🇸

Burke Pharmaceutical Research, Hot Springs, Arizona, United States

🇺🇸

DermResearch, Austin, Texas, United States

Efficacy and Safety Study of CD 2027 Spray in Subjects With Plaque-type Psoriasis

Phase 2
Completed
Conditions
Psoriasis
Interventions
First Posted Date
2008-10-01
Last Posted Date
2022-08-23
Lead Sponsor
Galderma R&D
Target Recruit Count
88
Registration Number
NCT00763555
Locations
🇨🇦

K. Papp Clinical Research, Inc., Waterloo, Ontario, Canada

🇨🇦

North Bay Dermatology Centre, North Bay, Ontario, Canada

🇺🇸

Minnesota Clinical Study Center, Fridley, Minnesota, United States

and more 3 locations

Efficacy/Safety/Subject Satisfaction/Duration of Response of Clobetasol Propionate Spray vs Ointment in Plaque Psoriasis

Phase 4
Completed
Conditions
Plaque Psoriasis
Interventions
First Posted Date
2008-08-13
Last Posted Date
2022-08-23
Lead Sponsor
Galderma R&D
Target Recruit Count
250
Registration Number
NCT00733954
Locations
🇺🇸

Solano Clinical Research, Vallejo, California, United States

🇺🇸

Henry Ford Medical Center, Detroit, Michigan, United States

🇺🇸

Baylor Research Institute - Dermatology Research, Dallas, Texas, United States

and more 3 locations

Evaluate Efficacy, Safety & Subject Satisfaction of Pain Management With Pliaglis® Cream for Dermal Filler Injections

First Posted Date
2008-07-16
Last Posted Date
2022-08-23
Lead Sponsor
Galderma R&D
Target Recruit Count
51
Registration Number
NCT00716443
Locations
🇺🇸

Premier Clinical Research, Spokane, Washington, United States

🇺🇸

Sadick Dermatology, New York, New York, United States

🇺🇸

Skin and Cancer Associates, Center for Cosmetic Enhancement, Aventura, Florida, United States

and more 1 locations
© Copyright 2025. All Rights Reserved by MedPath